Rational therapy of ocular surface bacterial infections with fluoroquinolones Review article

Article Sidebar

PDF PDF (Język Polski)


Published: Jun 30, 2022
DOI: https://doi.org/10.24292/01.OT.260522
Keywords:
bacterial conjunctivitis, bacterial keratitis, ophthalmic fluoroquinolones, moxifloxacin

Main Article Content

Ewelina Trojacka
1. Chair and Department of Ophthalmology, II Faculty of Medicine, Medical University of Warsaw; Independent Public Clinical Ophthalmology Hospital in Warsaw. 2. The Eye Laser Microsurgery Centre. Clinic of prof. Jerzy Szaflik
Justyna Izdebska
1. Chair and Department of Ophthalmology, II Faculty of Medicine, Medical University of Warsaw; Independent Public Clinical Ophthalmology Hospital in Warsaw. 2. The Eye Laser Microsurgery Centre. Clinic of prof. Jerzy Szaflik
http://orcid.org/0000-0002-5289-6860

Abstract

There are many mechanisms, that protect healthy ocular surface from invasion of pathogenic bacteria. Infection and inflammation develop on the ocular surface in case of damaging natural defensive barrier. One of the most common ocular surface infections are bacterial conjunctivitis and keratitis. Rational therapy of these diseases should be based on antibiotics that have broad antimicrobial spectrum, good efficacy and safety. All these qualities have fluoroquinolones: ofloxacin, levofloxacin and moxifloxacin.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Trojacka E, Izdebska J. Rational therapy of ocular surface bacterial infections with fluoroquinolones. Ophthatherapy [Internet]. 2022Jun.30 [cited 2024Nov.21];9(2):119-23. Available from: https://journalsmededu.pl/index.php/ophthatherapy/article/view/1915
Issue
Vol 9 No 2 (2022)
Section
Conservative treatment
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Caiado AVPR, Morato R, Abreu de Lima P et al. Epidemiology of conjunctivitis in the emergency department of reference hospital in Goianiai. Invest Ophthalmol Vis Sci. 2018; 59(9): 3780.
2. Azari AA, Barney NP. Conjunctivitis. JAMA. 2013; 310(16):1721-9.
3. Ting DSJ, Ho CS, Deshmukh R et al. Infectious keratitis: an update on epidemiology, causative microorganisms, risk factors, and antimicrobial resistance. Eye. 2021; 35: 1084-101.
4. Pippin MM, Le JK. Bacterial Conjunctivitis. StatPearls Publishing, 2022.
5. Blondeau JM, Zhao X, Hansen G et al. Mutant Prevention Concentrations of Fluoroqinolones for Clinical Isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2001; 45(2): 433-8.
6. Wagner RS, Abelson MB, Shapiro A et al. Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentration
in human conjunctival tissue. Arch Ophthalmol. 2005; 123: 182-3.
7. Yagci R, Oflu Y, Dincel A et al. Penetration of second-, third-, and fourth- generation of topical fluoroqinolone into aqueous and vitreous humour in a rabbit endophthalmitis model. Eye. 2007; 21: 990-4.
8. Oum BS, Kim NM, Lee JS et al. Effects of fluoroquinolone eye solutions without preservatives on human corneal epithelial cells in vitro. Ophthalmic Res. 2014; 51(4): 216-23.
9. Han KE, Chung WS, Kim TI et al. Epithelial wound healing after cataract surgery comparing two different topical fluoroqinolones. Yonsei Med J. 2014; 55(1): 197-202.
10. Tsai T, Chen W, Hu F. Comparison of fluoroqinolones: cytotoxicity on human corneal epithelial cells. Eye. 2010; 24; 909-17.
11. Lai WW, Chu KO, Chan KP et al. Differential aqueous and vitreous concentrations of moxifloxacin and ofloxacin after topical administration one hour before vitrectomy. Am J Ophthalmol. 2007; 144: 315-8.
12. Kowalski RP, Dhaliwal DK, Karenchak LM et al. Gatifloxacin and moxi oxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol. 2003; 136: 500-5.
13. Hanet MS, Jamart J, Chaves AP. Fluoroqinolones or fortified antibiotics for treating bacterial keratitis: systemic review and meta-analysis of comparative studies. Can J Ophthalmol. 2012; 47(6): 493-9.
14. Khoo P, Aguas MPC, Watson S. Comparison of combination forti ed antibiotics and monotherapy fluoroquinolone in the treatment of bacterial keratitis. Invest Ophthalmol Vis Sci. 2020; 61(7): 5216.
15. Haas W, Pillar CM, Torres M et al. Monitoring antibiotic resistance in ocular microorganisms: results from the Antibiotic Resistance Monitoring in Ocular microrganisms (ARMOR. 2009 surveillance study. Am J Ophthalmol. 2011; 152(4): 567-74.